BioStem Technologies, Inc. (BSEM)
USD 8.3
(1.22%)
USD 8.3
(1.22%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 15.9 Million USD | 114.45% |
| 2022 | 7.41 Million USD | -12.39% |
| 2021 | 8.46 Million USD | 1.98% |
| 2020 | 8.3 Million USD | 17.07% |
| 2019 | 7.09 Million USD | 18.72% |
| 2018 | 5.97 Million USD | 280.48% |
| 2017 | 1.56 Million USD | -34.83% |
| 2016 | 2.4 Million USD | 86.44% |
| 2015 | 1.29 Million USD | 546.94% |
| 2014 | 199.7 Thousand USD | 150.22% |
| 2013 | 79.81 Thousand USD | 16.51% |
| 2012 | 68.5 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 72.34 Million USD | 85.36% |
| 2024 Q1 | 39.03 Million USD | 144.64% |
| 2023 Q2 | 8.55 Million USD | 11.58% |
| 2023 Q3 | 9.33 Million USD | 9.19% |
| 2023 FY | 15.95 Million USD | 115.13% |
| 2023 Q4 | 15.95 Million USD | 70.83% |
| 2023 Q1 | 7.66 Million USD | 3.36% |
| 2022 Q3 | 6.9 Million USD | -4.36% |
| 2022 FY | 7.41 Million USD | -12.39% |
| 2022 Q4 | 7.41 Million USD | 7.33% |
| 2022 Q1 | 6.77 Million USD | -19.99% |
| 2022 Q2 | 7.22 Million USD | 6.67% |
| 2021 Q3 | 8.53 Million USD | -1.06% |
| 2021 FY | 8.46 Million USD | 1.98% |
| 2021 Q4 | 8.46 Million USD | -0.87% |
| 2021 Q1 | 8.51 Million USD | 2.61% |
| 2021 Q2 | 8.63 Million USD | 1.33% |
| 2020 Q3 | 8.35 Million USD | 5.88% |
| 2020 Q1 | 7.24 Million USD | 2.19% |
| 2020 Q4 | 8.3 Million USD | -0.64% |
| 2020 FY | 8.3 Million USD | 17.07% |
| 2020 Q2 | 7.89 Million USD | 8.91% |
| 2019 FY | 7.09 Million USD | 18.72% |
| 2019 Q4 | 7.09 Million USD | 0.0% |
| 2018 Q1 | 1.93 Million USD | 20.93% |
| 2018 FY | 5.97 Million USD | 280.48% |
| 2018 Q2 | 2.62 Million USD | 35.89% |
| 2017 Q1 | 1.63 Million USD | -31.98% |
| 2017 Q3 | 1.45 Million USD | -11.33% |
| 2017 Q4 | 1.59 Million USD | 10.01% |
| 2017 FY | 1.56 Million USD | -34.83% |
| 2017 Q2 | 1.63 Million USD | -0.0% |
| 2016 Q1 | 1.31 Million USD | 1.99% |
| 2016 Q4 | 2.4 Million USD | 5.15% |
| 2016 FY | 2.4 Million USD | 86.44% |
| 2016 Q2 | 1.85 Million USD | 40.84% |
| 2016 Q3 | 2.29 Million USD | 23.44% |
| 2015 Q1 | 183.18 Thousand USD | -8.27% |
| 2015 Q2 | 379.12 Thousand USD | 106.96% |
| 2015 Q4 | 1.29 Million USD | 118.97% |
| 2015 Q3 | 590.02 Thousand USD | 55.63% |
| 2015 FY | 1.29 Million USD | 546.94% |
| 2014 Q4 | 199.7 Thousand USD | 25.34% |
| 2014 Q1 | 69.24 Thousand USD | -13.25% |
| 2014 Q2 | 142.42 Thousand USD | 105.7% |
| 2014 Q3 | 159.33 Thousand USD | 11.87% |
| 2014 FY | 199.7 Thousand USD | 150.22% |
| 2013 Q1 | 68.5 Thousand USD | 0.0% |
| 2013 Q2 | 102.65 Thousand USD | 49.85% |
| 2013 Q3 | 90.26 Thousand USD | -12.07% |
| 2013 Q4 | 79.81 Thousand USD | -11.58% |
| 2013 FY | 79.81 Thousand USD | 16.51% |
| 2012 FY | 68.5 Thousand USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -57876.404% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -68.02% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 78.054% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1866.467% |
| Rebus Holdings, Inc. | 5.24 Million USD | -203.408% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 73.049% |
| Qrons Inc. | 1.48 Million USD | -968.35% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -1197.056% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 78.771% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -35484.095% |
| Skye Bioscience, Inc. | 14.07 Million USD | -13.022% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 70.163% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -65.984% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -3672.741% |
| SQZ Biotechnologies Company | 50.03 Million USD | 68.215% |
| Intellipharmaceutics International Inc. | 12 Million USD | -32.442% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -312.955% |
| Mesoblast Limited | 188.44 Million USD | 91.56% |
| Marizyme, Inc. | 26.67 Million USD | 40.378% |
| Genus plc | 485 Million USD | 96.721% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -172.218% |
| Pharming Group N.V. | 244.07 Million USD | 93.484% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -691.226% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -532.059% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -318.544% |
| ContraFect Corporation | 32.53 Million USD | 51.109% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -702.736% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -315.521% |
| IMV Inc. | 37.93 Million USD | 58.071% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -35.035% |
| MultiCell Technologies, Inc. | 1617.67 USD | -983083.653% |
| ONE Bio Corp. | 27.49 Million USD | 42.156% |
| Accustem Sciences Inc. | 1.07 Million USD | -1373.693% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 79.456% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -651.969% |
| Q BioMed Inc. | 8.13 Million USD | -95.559% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 80.823% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -209.066% |
| Biomind Labs Inc. | 1.49 Million USD | -961.293% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 86.603% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -75.894% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 13.578% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1009.22% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -11092.981% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -7808.206% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -176.804% |
| GB Sciences, Inc. | 5.41 Million USD | -193.576% |
| Alpha Cognition Inc. | 7.16 Million USD | -121.984% |
| HST Global, Inc. | 593.59 Thousand USD | -2579.389% |
| CSL Limited | 18.62 Billion USD | 99.915% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1163.084% |
| Halberd Corporation | 728.71 Thousand USD | -2082.551% |
| Enzolytics Inc. | 365.26 Million USD | 95.646% |
| Agentix Corp. | 2.51 Million USD | -533.512% |
| Resverlogix Corp. | 67.39 Million USD | 76.401% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1796.275% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 96.426% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -827.927% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 35.728% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -33.618% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -333.941% |
| AVAX Technologies, Inc. | 3.99 Million USD | -298.239% |
| Zenith Capital Corp. | 27.56 Thousand USD | -57590.402% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.8% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -6564.32% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -325.907% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -2236.057% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -486.533% |
| Kadimastem Ltd | 3.5 Million USD | -353.788% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -23663.491% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 68.358% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -3322.574% |
| LadRx Corporation | 2.2 Million USD | -622.766% |
| Cell Source, Inc. | 15.8 Million USD | -0.62% |
| Regen BioPharma, Inc. | 5.45 Million USD | -191.422% |
| Regen BioPharma, Inc. | 5.45 Million USD | -191.422% |
| NovAccess Global Inc. | 7.86 Million USD | -102.331% |
| Affymax, Inc. | 8.87 Million USD | -79.288% |
| Itoco Inc. | 1.65 Million USD | -862.082% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -675.246% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -162.931% |
| Mobile Lads Corp. | 1.31 Million USD | -1110.864% |
| CytoDyn Inc. | 127.89 Million USD | 87.564% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -37950.353% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -915.379% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -43.995% |
| SYBLEU INC | 681.41 Thousand USD | -2234.072% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -160.651% |
| International Stem Cell Corporation | 5.27 Million USD | -201.396% |
| Bioxytran, Inc. | 3.24 Million USD | -389.45% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -2441.457% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -244.471% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 61.204% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 28.567% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -685.266% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -190.337% |
| Neutra Corp. | 973.52 Thousand USD | -1533.713% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 45.185% |
| PureTech Health plc | 125.58 Million USD | 87.335% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -323.32% |
| IXICO plc | 1.9 Million USD | -736.959% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 22.526% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 84.607% |
| CSL Limited | 18.62 Billion USD | 99.915% |
| Cellectis S.A. | 249.36 Million USD | 93.622% |